CRC incidence will be over 490,000 cases by 2018 in the seven major markets. This large patient base will translate into a high commercial potential for the development of novel, more effective therapies. Currently, there are 77 agents in development for CRC, 4 of which are in late-phase development. Collectively, they are forecast to achieve sales of $1,398m by 2018.
Scope
Examination of the CRC pipeline with in-depth clinical and commercial profiles of Phase III candidates
Seven major pharmaceutical market sales forecasts for Phase III pipeline products through to 2018
Segmentation and analysis of the current CRC pipeline by developmental phase, drug class and company
Insight and analysis of market potential including commercial opportunity, epidemiology and discussion of unmet needs
Highlights
The CRC pipeline consists of 77 drugs, of which 60% are molecular targeted therapies (MTTs), 22% are immunotherapies, and 17% are cytotoxic therapies. MTTs constitute the bulk of the CRC pipeline. This is in line with R&D in other tumor types, where there is a shift away from standard cytotoxic therapies towards MTTs and personalized medicine.
The late-phase CRC pipeline consists only of MTTs. Except for one agent; all the others are being investigated in previously-treated patients. Drug developers appear to be pursuing approval for treatment in the second-line setting where barriers to market entry are lower and the high level of unmet need may facilitate a drug's uptake and approval.
Aflibercept (VEGF-Trap; Regeneron/Sanofi-Aventis) is forecast to achieve the highest level of sales among the late-phase pipeline candidates in the CRC market, generating £604m by 2018 in the seven major pharmaceutical markets.
Reasons to Purchase
Identify key drugs and companies within the CRC pipeline based on sales forecasts to 2018 and Datamonitor drug assessment.
Characterize unmet need and poorly served patient subsets within the CRC market and assess the potential for pipeline products to fulfil them.
Segmentation and analysis of the current CRC pipeline by developmental phase, drug class, company and indication.
(0 items)
